Salvage Radiation Treatment for Primary Refractory Diffuse Large B-cell Lymphoma After Chimeric Antigen Receptor (CAR) T-cell Therapy: A Case Report.
BACKGROUND
Treatment of refractory/relapsing diffuse large B cell (R/R DLBCL) lymphoma remains a challenge. Radiation therapy (RT) has versatile roles in R/R DLBCL treatment: it can be used in the peri-transplant setting for transplant-eligible candidates, or as a salvage or palliation therapy depending on the extent of the disease in transplant-ineligible patients. The introduction of chimeric antigen receptor (CAR) T-cell therapy has changed the landscape of R/R DLBCL. RT has been used as a bridging therapy to CAR T-cell therapy in order to control disease progression during its manufacturing period. However, optimal RT and CAR T-cell therapy integration is still unknown. Salvage strategies for R/R DLBCL post-CAR T-cell therapy have been little studied.


CASE REPORT
Here, we present a case of primary refractory DLBCL with residual disease post-CAR T-cell therapy successfully treated with salvage RT.


CONCLUSION
Radiotherapy could be an effective salvage strategy for R/R DLBCL post-CAR T-cell therapy. Exact mechanisms await exploring.
['Wang|Kaidi|K|', 'Prabhu|Arpan V|AV|', 'Sasapu|Appalanaidu|A|', 'Lewis|Gary D|GD|']
D064987:Cell- and Tissue-Based Therapy D005260:Female D006801:Humans D016403:Lymphoma, Large B-Cell, Diffuse D008875:Middle Aged D009364:Neoplasm Recurrence, Local D018365:Neoplasm, Residual D000076962:Receptors, Chimeric Antigen D016879:Salvage Therapy D013601:T-Lymphocytes
R/R DLBCL radiation therapy CAR T-cell therapy post-CAR T salvage therapy